SFGP
CUE icon

Stonebridge Financial Group (Pennsylvania)’s Cue Biopharma CUE Stock Holding History

Stonebridge Financial Group (Pennsylvania)’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2
Closed -$56 – 384
2025
Q1 		$56 Hold
2
– – ﹤0.01% 990
2024
Q4 		$68 Buy
+2
New +$75 ﹤0.01% 818

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Stonebridge Financial Group (Pennsylvania)'s CUE Position: Q2 2025 in Review

Stonebridge Financial Group (Pennsylvania) sold out of Cue Biopharma (CUE) in Q2 2025, closing a stake of 2 shares — an estimated $56 sold.

Stonebridge Financial Group (Pennsylvania) first reported a position in CUE in Q4 2024 and held it in 2 quarters. The position peaked at $68 in Q4 2024. 47 funds tracked by Wall St. Rank hold CUE as of Q2 2025.

  • Stonebridge Financial Group (Pennsylvania) reported no remaining Cue Biopharma position as of Q2 2025 after selling out during the quarter.
  • Stonebridge Financial Group (Pennsylvania) sold 2 Cue Biopharma shares in Q2 2025, an estimated $56.
  • Stonebridge Financial Group (Pennsylvania) first reported a position in Cue Biopharma in Q4 2024 and held it in 2 quarters.
  • Stonebridge Financial Group (Pennsylvania)'s Cue Biopharma position peaked at $68 in Q4 2024.
  • 47 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2025.

Based on Stonebridge Financial Group (Pennsylvania)'s 13F filing for Q2 2025, filed 24 Jul 2025.